No Data
OmniAb to Participate in the Jefferies Global Healthcare Conference
OmniAb, Inc. (NASDAQ:OABI) today announced that management will be participating at the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City. Management will be
Craig-Hallum Reaffirms Their Buy Rating on OmniAb (OABI)
OmniAb Presents High-Throughput Single B-cell Screening XPloration Data at the 20th Annual PEGS Boston Summit
Technical synergies between xPloration, OmniFlic, OmniClic and OmniDeep enable new bispecific antibody discovery workflows for OmniAb's partners OmniAb, Inc. (NASDAQ:OABI) today announced its
Benchmark: The OmniaB (OABI.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $8.00.
Benchmark: The OmniaB (OABI.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $8.00.
Benchmark Reiterates Buy on OmniAb, Maintains $8 Price Target
Benchmark analyst Robert Wasserman reiterates OmniAb with a Buy and maintains $8 price target.
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Green Thumb Industries (OtherGTBIF) and OmniAb (OABI)